In line with our findings, a recent study in breast cancer reported that higher levels of ex vivo IgG responses to breast cancer antigens were associated with shorter survival and lower tumor-infiltrating CD8+ T cell counts [35]. This evidence concerns the gene CD8A and neoplasm.